Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arius and Avid Bioservices sign manufacturing agreement
Avid has begun manufacturing a supply of the drug for human clinical trials which Arius plans to initiate in 2008. Arius has also scheduled a pre-IND meeting with
Avid has begun manufacturing a supply of the drug for human clinical trials which Arius plans to initiate in 2008. Arius has also scheduled a pre-IND meeting with
Under the terms of the acquisition agreement, Amarin will acquire 100% of the issued share capital of Ester for initial consideration of $15 million, of which $5 million
Under the collaboration, BioSeek will apply its BioMAP Systems to evaluate a number of UCB compounds across several target classes, in support of target differentiation, lead development, and
Under the 2005 collaboration agreement, Rigel will receive a $5 million milestone payment from Pfizer for the commencement of this study. Pfizer retains exclusive rights to R343 and
Under the terms of the agreement, Millipore’s bioprocess division and Rohm and Haas Ion Exchange Resins will develop improved ion exchange chromatography products for manufacturing biologic drugs. Millipore
Under the agreement Immtech will receive an initial license fee of $3 million and up to an additional $13 million if pafuramidine achieves European regulatory approval and pricing
The filing is based on the results of two fixed-dose, randomized, double-blind, placebo-controlled efficacy and safety studies that evaluated rotigotine for the treatment of moderate-to-severe idiopathic Restless Legs
The initial stage of the trial will assess the bioavailability of a single-dose oral suspension in 16 healthy elderly subjects. The second stage will be a randomized, double-blind,
In July 2007, AxoGen established itself in the nerve regeneration field with the launch of Avance nerve graft for peripheral nerve repair. Jamie Grooms, CEO and co-founder of
Centocor has submitted a biologics license application with the FDA and Janssen-Cilag International has submitted a marketing authorization application to the European Medicines Agency. The submissions are based